Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Project BioShield” Offers Funding Source For Biotech, McClellan Tells BIO

Executive Summary

The biotechnology industry should embrace Project BioShield as a guaranteed market for innovative counter-terrorism technologies, Commissioner McClellan said during the Biotechnology Industry Organization CEO and investor conference Feb. 27 in New York

You may also be interested in...



BIO Gets Pep Talk From Commander-In-Chief; Is Boom-And-Bust Cycle Over?

The recent rebound in the biotechnology sector is "for real," FDA Commissioner McClellan declared during the Biotechnology Industry Organization annual meeting in Washington, D.C. June 23

BIO Gets Pep Talk From Commander-In-Chief; Is Boom-And-Bust Cycle Over?

The recent rebound in the biotechnology sector is "for real," FDA Commissioner McClellan declared during the Biotechnology Industry Organization annual meeting in Washington, D.C. June 23

“Project BioShield” Model Could Apply More Broadly, FDA Commissioner Says

"Project BioShield" offers a model that policymakers should consider to encourage research in infectious diseases, FDA Commissioner McClellan told the Commonwealth Club in San Francisco June 9

Related Content

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel